Chemed/$CHE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Chemed

Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. Through its subsidiaries, the company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.

Ticker

$CHE
Sector

Primary listing

NYSE

Employees

15,695

Chemed Metrics

BasicAdvanced
$6.3B
22.39
$19.48
0.43
$2.10
0.55%

What the Analysts think about Chemed

Analyst ratings (Buy, Hold, Sell) for Chemed stock.

Bulls say / Bears say

VITAS net patient revenue increased 5.8% to $396.2 million, driven by a 6.1% rise in days-of-care and a 4.2% increase in Medicare reimbursement rates, reflecting strong demand for end-of-life services (BusinessWire)
Total revenue climbed 3.8% to $618.8 million, marking the company’s tenth straight quarter of year-over-year revenue growth across its main businesses (BusinessWire)
Chemed closed Q2 2025 with $249.9 million in cash and zero debt, keeping a strong balance sheet to support growth plans and shareholder returns (SEC.gov)
GAAP diluted EPS dropped 23.2% to $3.57 in Q2, impacted by Medicare cap issues and increased operating costs at VITAS (BusinessWire)
Roto-Rooter's adjusted EBITDA fell 18.7% to $48.6 million, underlining margin pressure from higher digital marketing and labor expenses (BusinessWire)
VITAS’ adjusted EBITDA margin narrowed by 163 basis points to 16.2%, indicating rising cost pressures and an increasingly unfavorable mix in hospice care (BusinessWire)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.

Chemed Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Chemed Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CHE

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs